VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS

Von Willebrand Disease Treatment MarketSize and Trends

Rapid FDA approvals is expected to fuel the growth of von Willebrand Disease (vWD) treatment market

Rapid approvals of vWD treatment therapies and drugs from FDA and marketing approvals in different region are expected to fuel growth of von Willebrand Disease (vWD) treatment market in near future. In 2015, the U.S. Food and Drug Administration (FDA) was granted approval for Octapharma’s WILATE a replacement therapy for patients suffering from von Willebrand Disease (vWD).

In 2017, European Medicines Agency (EMA) granted authorization for the marketing of VEYVONDI to prevent and treat von Willebrand Disease. VEYVONDI is a replacement therapy developed by Shire plc, which was FDA approved in 2015. Rapid marketing permission of drugs is expected to fuel Von Willebrand Disease (vWD) Treatment Market in near future. The major factor restraining the growth of von Willebrand Disease (vWD) treatment market is lack of awareness about disease and its diagnosis as it is a very rare disease.